1-5 of 5
Mohamed Zaki, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study

Katja Weisel, MD, Meletios A Dimopoulos, MD, Philippe Moreau, Munci Yagci, Alessandra Larocca, MD, Abraham S. Kanate, MD, Filiz Vural, Nicola Cascavilla, MD, Supratik Basu, MBBS, MD FRCP, FRCPath, Peter Johnson, Peter D. Byeff, MD, Marek Hus, Paula Rodriguez Otero, MD, Kosei Matsue, MD PhD, Ercan Muelduer, Pekka Anttila, MD, Patrick Hayden, Maria-Theresa Krauth, MD, Dina Ben-Yehuda, MD, Larisa P. Mendeleeva, MD PhD Prof, Shien Guo, Lea Purnomo, Xin Yu, Lara Grote, Tsvetan Biyukov, MD, Mohamed Zaki, MD PhD, Paul Richardson
Journal: Blood
Blood (2018) 132 (Supplement 1): 1960.
https://doi.org/10.1182/blood-2018-99-112155
Published: 2018
Journal Articles

Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial

Meletios A Dimopoulos, MD, Katja Weisel, MD, Philippe Moreau, Larry Anderson, MD PhD, Darrell J White, MD, Jesus F San-Miguel, MD PhD, Pieter Sonneveld, MD PhD, Monika Engelhardt, MD, Matthew W Jenner, Alessandro Corso, MD, Jan Dürig, Michel Pavic, MD, Morten Salomo, Xin Yu, Tuong Vi Nguyen, Amine Bensmaine, Teresa Peluso, Mohamed Zaki, MD PhD, Paul Richardson
Journal: Blood
Blood (2018) 132 (Supplement 1): 3278.
https://doi.org/10.1182/blood-2018-99-111869
Published: 2018
Journal Articles

Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results

Paul G. Richardson, MD, David S. Siegel, MD, PhD, Ravi Vij, MD, Craig C. Hofmeister, MD, Sundar Jagannath, MD, Christine Chen, MD, Sagar Lonial, MD, Andrzej J Jakubowiak, MD, PhD, Nizar J Bahlis, MD, Rachid Baz, MD, Gail Larkins, RN, Min Chen, PhD, Mohamed Zaki, MD, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2011) 118 (21): 634.
https://doi.org/10.1182/blood.V118.21.634.634
Published: 2011
Journal Articles

Simulation of Clinical Outcome for Pomalidomide Plus Low-Dose Dexamethasone in Patients with Refractory Multiple Myeloma Based on Week 8 M-Protein Response

Rene Bruno, PhD, Fredrik Jonsson, PhD, Mohamed Zaki, MD, PhD, Christian Jacques, MD, Arlene S Swern, PhD, Paul G. Richardson, MD, Vincent Rajkumar, MD, Laurent Claret, PhD
Journal: Blood
Blood (2011) 118 (21): 1881.
https://doi.org/10.1182/blood.V118.21.1881.1881
Published: 2011
Journal Articles

CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) - Preliminary Results of Subjects with Castleman’s Disease from a Phase 1 Study in Selected Hematological Malignancies.

Frits VanRhee, MD, PhD, FRCPath, MRCP, Luis Fayad, MD, Hossein Borghaei, OD, MS, Peter M. Voorhees, MD, Robert Z. Orlowski, MD,PhD, Richard R. Furman, MD, Mohamed Zaki, MD,PhD, Uma Prabhakar, Trina Jiao, Christine Lihou, Carlos A. Garay, MD, Razelle Kurzrock, MD, FACP
Journal: Blood
Blood (2006) 108 (11): 2728.
https://doi.org/10.1182/blood.V108.11.2728.2728
Published: 2006